This study evaluated the safety and preliminary efficacy of an all-oral triple regimen consisting of olaparib (a PARP inhibitor), metronomic cyclophosphamide (a chemotherapy agent), and metformin (a PI3K/Akt/mTOR inhibitor) in patients with recurrent endometrial carcinomas. This evidence concerns the gene MTOR and endometrial carcinoma.